Thorium-227 (t
1/2 = 18.72 d) is a promising alpha-emitting radiotherapeutic nuclide for treatment of bone metastases. The daughter nuclide
223Ra, which have been used in clinical study for human, also decays via several alpha-emitting nuclides to stable
207Pb. The decay and growth patterns of radioactivity of
227Th and
223Ra after accumulation in bone are specific for each nuclide. We attempt here to evaluate and compare the myelotoxicities of
227Th-EDTMP and
223Ra in rats.
Seven-week-old Sprague-Dawley rats were injected
227Th-EDTMP or
223RaCl
2. The body weight and blood cells (RBCs, WBCs, platelets) of each rat were counted before injection and more than 8 weeks after injection.
A rat injected 8 MBq/kg b.w. of
223Ra died 9 day postinjection. The rats injected more than 250 kBq/kg b.w. of
223Ra showed decrease of WBCs and platelets. In the case of
227Th injection, a rat injected 8 MBq/kg b.w. died 8 day postinjection. On the other hand, the rats injected 4 and 2 MBq/kg b.w. died 4 and 6 weeks postinjection, respectively. The rats injected more than 500 kBq/kg b.w. showed weight loss and decrease of RBCs, WBCs, and platelets.
The myelotoxicity of
227Th-EDTMP showed specific pattern and may correlate to the decay and growth pattern of
227Th and its progeny radioactivity.
View full abstract